Hemispherx Not Among 4 to Get H1N1 Flu Contracts
Stock quotes in this article:
HEB
The Food and Drug Administration's review of Ampligen for CFS is now seven weeks overdue. Hemispherx has said little about the delay other than that the agency needed a couple more weeks to issue an approval decision due to staffing shortages. That two-week extension came and went more than a month ago.
Hemispherx shares were down 2.8% to $2.06 in recent trading.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
